SUPG will be at 4.50 or higher. Believe strongly that MOGN analyst meeting and SUPG Quarter update will have extra news about several developments. Believe we'll see further results in phase 3 study on Dacogen relating to AML. Second- updates on MP-470 and (MP-529 an oral delivery drug). Third cash position on SUPG very strong. Updates on Nipent new patent. Forth revenue picture update and breakeven right around the corner. Montigen pipeline updates and expansion into several clinical candidates. The Dacogen approval proved that SUPG can and will get drugs to market. Look for these important updates. Would not be surprised if they buy another company out with an drug nearing clinical trials.